Please check your internet connection and try again.
# Flupentixol and Melitracen
## Overview
Flupentixol/melitracen is a fixed-dose combination product containing a thioxanthene antipsychotic (flupentixol) and a tricyclic antidepressant (melitracen). It is marketed primarily in various international markets for the short-term treatment of anxiety, depression, and apathy. It is not FDA-approved for use in the United States.
## Primary Indications
* Psychogenic depression.
* Depressive neuroses.
* Masked depression.
* Psychosomatic affections accompanied by anxiety and apathy.
* Menopausal depressions.
* Dysphoria and depression in alcoholics/drug addicts.
## Adult Dosing
* **Initial Dose:** 1 tablet (0.5 mg flupentixol / 10 mg melitracen) twice daily (morning and noon).
* **Maximum Dose:** 4 tablets daily. If no improvement is observed after one week at the maximum dose, the drug should generally be discontinued.
* **Maintenance:** 1 tablet in the morning.
* **Note:** Due to the stimulating effect of melitracen, evening dosing should be avoided to prevent insomnia.
## Pediatric Dosing
Safety and efficacy in children have not been established. Use is generally not recommended in the pediatric population.
## Dose Adjustments
* **Geriatric Patients:** Use the lowest effective dose. Increased sensitivity to anticholinergic and extrapyramidal side effects is common.
* **Hepatic/Renal Impairment:** No specific guidelines exist; caution is advised as both components undergo hepatic metabolism. Use with caution in patients with severe impairment.
## Contraindications
* Hypersensitivity to flupentixol or melitracen.
* Circulatory collapse, depressed levels of consciousness (e.g., alcohol, barbiturate, or opioid intoxication).
* Blood dyscrasias.
* Recent myocardial infarction.
* Cardiac conduction defects (heart block).
* Current mania or chronic overstimulation.
* Pheochromocytoma.
## Adverse Effects
* **Common:** Dry mouth, insomnia, restlessness/agitation, dizziness, tremor, blurred vision.
* **Serious:** Extrapyramidal symptoms (EPS), tardive dyskinesia, neuroleptic malignant syndrome (NMS), QT interval prolongation, cardiac arrhythmias, urinary retention, and seizures.
## Key Drug Interactions
* **CNS Depressants:** Enhances effects of alcohol, barbiturates, and sedatives.
* **MAO Inhibitors:** Risk of hypertensive crisis; must have a washout period of at least 14 days.
* **Antihypertensives:** Potential for additive hypotension (e.g., guanethidine, clonidine).
* **Anticholinergics:** Enhances anticholinergic effects.
* **QT Prolonging Agents:** Increased risk of ventricular arrhythmias with other QT-prolonging medications.
## Monitoring
* Baseline and periodic ECG (especially in patients with underlying cardiac disease).
* Monitor for signs of EPS (dystonia, akathisia, parkinsonism).
* Monitor for signs of NMS (hyperpyrexia, muscle rigidity).
* Assess for suicidal ideation, especially during early treatment.
* Blood pressure and heart rate.
## Clinical Pearls
* **Stimulant Profile:** Unlike many antidepressants, this combination is activating; it is specifically indicated for patients presenting with lethargy and apathy.
* **Discontinuation:** Abrupt withdrawal should be avoided to prevent withdrawal symptoms (restlessness, nausea, recurrence of depression). Taper gradually.
* **Duration:** Intended for short-term use due to the risk of accumulation and dependence.
* **Regulatory Note:** This combination is not available or "Generally Recognized as Safe and Effective" by the US FDA. Clinical protocols may vary significantly by country.
***
**Educational Disclaimer:** This information is for educational purposes only. Always consult current local prescribing information, clinical guidelines, and the manufacturer’s Summary of Product Characteristics (SmPC) before ordering or administering any medication. Pharmacists and clinicians must exercise professional judgment based on the individual patient's condition.
